文献速递脊柱关节炎

脊柱关节炎外周表现评估及生物/靶向合成DMARDs疗效的系统文献综述

Peripheral manifestations in spondyloarthritis: a systematic literature review on their assessment and the effect of biological/targeted synthetic DMARDs.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该系统文献综述纳入100项axSpA和4项pSpA试验,评估外周关节炎、附着点炎和指趾炎的报告频率及b/tsDMARDs疗效。axSpA试验中仅54%评估外周关节炎、64%评估附着点炎、10%评估指趾炎,b/tsDMARDs效应多为小到中等;pSpA试验均评估报告外周表现,效应中等。

要点

  • axSpA试验中外周表现评估报告不一致,指趾炎评估仅10%。
  • b/tsDMARDs对外周表现效应小到中等,基线有外周受累者效应更高。
  • pSpA试验均评估报告外周表现,b/tsDMARDs效应中等。

核心结论

  • axSpA试验中外周表现评估和报告不一致,b/tsDMARDs对外周表现有中小效应,可能因未在基线受累人群评估而被低估。

研究设计与样本

  • 系统文献综述,纳入100项axSpA和4项pSpA的b/tsDMARDs对照试验,排除银屑病关节炎。

主要发现

  • axSpA中54%评估外周关节炎,64%评估附着点炎,10%评估指趾炎;评估后报告率分别为69%、72%、10%。
  • axSpA中最常用工具:44关节计数评估外周关节炎(48%),MASES评估附着点炎(88%),指趾计数评估指趾炎(40%)。
  • axSpA中SMD范围0.26至-1.18,提示b/tsDMARDs效应主要为小到中等,基线有外周受累者效应更高。
  • pSpA中外周表现均评估报告,SMD范围-0.10至-1.22,效应一般为中等。

关键数值与推荐

  • axSpA中外周关节炎评估率54%、报告率69%;附着点炎评估率64%、报告率72%;指趾炎评估率10%、报告率10%。
  • axSpA中44关节计数使用率48%,MASES使用率88%,指趾计数使用率40%;未使用DAS等复合指数。
  • axSpA中b/tsDMARDs疗效SMD范围0.26至-1.18;pSpA中SMD范围-0.10至-1.22。

临床怎么用

  • 临床解读axSpA试验外周表现数据时需注意评估和报告不一致,指趾炎数据尤其有限。
  • b/tsDMARDs对外周表现疗效证据支持小到中等效应,基线有外周受累者可能获益更明显。

局限性

  • 外周表现评估和报告不一致可能导致b/tsDMARDs效应被低估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Peripheral manifestations (peripheral arthritis/enthesitis/dactylitis) are frequent in axial spondyloarthritis (axSpA) yet, understudied. We (i) evaluated the assessment/reporting of peripheral manifestations in trials of biological or targeted synthetic DMARDs (b/tsDMARDs) for axSpA and peripheral SpA (pSpA), and (ii) synthesized the efficacy of b/tsDMARDs on these manifestations. METHODS: Systematic literature review (SLR) of controlled trials evaluating b/tsDMARDs in axSpA/pSpA (excluding psoriatic arthritis). Records were identified through previous SLRs informing ASAS-EULAR recommendations and updated searches. Outcomes included (i) frequency of assessment/reporting of peripheral arthritis/enthesitis/dactylitis and (ii) treatment efficacy of b/tsDMARDs on these peripheral manifestations [standardized mean differences (SMDs) or relative risk]. RESULTS: We included 100 axSpA and four pSpA trials. In axSpA, peripheral arthritis was assessed in 54%, enthesitis in 64% and dactylitis in only 10% of studies. When assessed, results were reported in 69%, 72% and 10% of studies, respectively, and often in all patients (instead of those affected at baseline). Most frequently used instruments were 44-joint count for peripheral arthritis (48%), Maastricht Ankylosing Spondylitis Enthesitis Score for enthesitis (88%) and digit count for dactylitis (40%). Composite indices like DAS were not used. SMDs (range 0.26 to -1.18) indicated mainly small-to-moderate b/tsDMARD effects, typically higher in patients with baseline peripheral involvement. In pSpA, peripheral manifestations were always assessed/reported, with generally moderate effects (SMD range -0.10 to -1.22). CONCLUSION: Peripheral manifestations are inconsistently assessed and reported in axSpA trials. While b/tsDMARDs have small-to-moderate effects on peripheral manifestations, these may be underestimated due to not being assessed in the population affected at baseline.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Webers C, Ortolan A, Nikiphorou E, et al. Peripheral manifestations in spondyloarthritis: a systematic literature review on their assessment and the effect of biological/targeted synthetic DMARDs. Rheumatology (Oxford). 2026. PMID: 41666292. doi:10.1093/rheumatology/keag042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。